High levels of IgM against methylglyoxal-modified apolipoprotein B100 are associated with less coronary artery calcification in patients with type 2 diabetes
Article first published online: 1 JUL 2011
© 2011 The Association for the Publication of the Journal of Internal Medicine
Journal of Internal Medicine
Volume 271, Issue 1, pages 82–89, January 2012
How to Cite
Engelbertsen, D., Anand, D. V., Fredrikson, G. N., Hopkins, D., Corder, R., Shah, P. K., Lahiri, A., Nilsson, J. and Bengtsson, E. (2012), High levels of IgM against methylglyoxal-modified apolipoprotein B100 are associated with less coronary artery calcification in patients with type 2 diabetes. Journal of Internal Medicine, 271: 82–89. doi: 10.1111/j.1365-2796.2011.02411.x
- Issue published online: 16 DEC 2011
- Article first published online: 1 JUL 2011
- Accepted manuscript online: 13 JUN 2011 04:40PM EST
Figure S1. Comparison of anti-MGO-apoB100 inhibition by pre-incubation of pooled plasma from type 2 diabetic patients with 100 μg mL−1 native or MGO-modified apoB100, human serum abumin (HSA), or human plasma fibronectin. Values are the mean of triplicate wells ± SD.
Figure S2. Scatter plot showing log CAC and normalized levels of IgM antibody against MGO-apoB100.
|JOIM_2411_sm_FigS1-S2.doc||239K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.